Anne Grünewald, PhD

Research section leader

Name: Anne Grünewald

Date of birth: February 27th, 1982

Place of birth: Chemnitz, Germany

Position/Title:  Bridge Professor (double affiliation with the University of Luxembourg) and Head of Mitochondrial Research Section in Lübeck

Address: Institute of Neurogenetics, Mitochondrial Research Section, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Phone: +49-451-2903351; Fax: +49-451-2903353

Email: anne.gruenewald@neuro.uni-luebeck.de  

2003: German Academy Exchange Service (DAAD) Fellow, Institute of Functional Genomics, Centre National de la Recherche Scientifique, Montpellier, France

2004-2005: Graduate Engineer Diploma in Biotechnology, European Neuroscience Institute (Laboratory of Prof S. Sigrist), University of Göttingen, Germany

2005-2008: PhD Thesis (Section of Clinical & Molecular Neurogenetics led by Prof. C. Klein, University of Lübeck, Germany; “Molecular characterisation of SGCE-associated myoclonus dystonia and PINK1-associated Parkinson’s disease”)

2006: Visiting Scientist, Department of Clinical Genetics (Laboratory of Prof. V. Bonifati), Erasmus University Medical Center, Rotterdam, The Netherlands

2007-2008: DAAD Fellow, Department of Clinical Neurosciences (Head: Prof. A.H.V. Schapira), University College London, UK

2009-2012: Research Associate and Head, Mitochondrial Function in Movement Disorders Junior Group, Institute of Neurogenetics, University of Lübeck, Germany

2010: Visiting Scientist, Kolling Institute of Medical Research (Laboratory of Prof. C. Sue), University of Sydney, Australia

2012-2015: German Research Foundation (DFG) Fellow and Research Associate, Wellcome Trust Centre for Mitochondrial Research (Head: Prof. D. Turnbull), Newcastle University, UK

2016-present: Assoc. Professor, National Research Fund Luxembourg (FNR) ATTRACT Fellow, Head of the Molecular and Functional Neurobiology Research Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

2018-present: Assoc. Professor (“Brückenprofessor”, W2 level), Head of the Mitochondrial Function in Movement Disorders Section, Institute of Neurogenetics, University of Lübeck, Germany

2003-2014: Travel Awards from the Guarantors of Brain, the Movement Disorders Society, the German Academic Exchange Service, Boehringer Ingelheim, the Felgenhauer and the GSK Foundation

2011-2013: Career Development Award from the Medical Faculty of the University of Lübeck

2012-2013: International Research Fellowship awarded by the German Research Foundation; Welcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle UK

2012: International Research Fellowship awarded by the German Academic Exchange Service; declined

2013-2014: Extension of International Research Fellowship by the German Research Foundation for postdoctoral studies at Newcastle University, Newcastle, UK

2014: “Sparkasse zu Lübeck AG” Founders Award

2016-2020: ATTRACT Career Development Award of the Luxembourg National Research Fund

Stipends and Scholarships

2011-2013: Career Development Award from the Medical Faculty of the University of Lübeck

2012-2013: International Research Fellowship awarded by the German Research Foundation, Welcome Trust Centre for Mitochondrial Research, Newcastle University, Newcastle UK

2013-2014: Extension of International Research Fellowship by the German Research Foundation for postdoctoral studies at Newcastle University, Newcastle, UK

2016-2020: ATTRACT Career Development Award of the Luxembourg National Research Fund (Tenure track, Associate Professor)

 

Grants (limited to current external funding and grants completed in 2018)

“Model-IPD: Modelling idiopathic Parkinson’s disease-associated somatic variation in dopaminergic neurons”

Principal Investigator: Anne Grünewald
Funding agency: Luxembourg National Research Fund
Funding period: 2016-2020
Amount: € 1,500,000

“Mitochondrial membrane potential and mtDNA blood biomarkers for stratification of mitochondrial Parkinson’s disease”

Co-Principal Investigator: Anne Grünewald
Funding agency: The Michael J. Fox Foundation
Funding period: 2018-2020
Amount: US$ 79,000 (for Luxembourg site)

“ProtectMove: Markers and Mechanisms of Reduced Penetrance in LRRK2 Mutation Carriers”

Principal Investigator: Anne Grünewald
Funding agency: Luxembourg National Research Fund
Funding period: 2017-2020
Amount: € 368,000

“Nucleo-Mito-Seq – Exploring genetic interactions between nuclear and mitochondrial somatic DNA variations in single postmortem PD neurons”

Co-Principal Investigators: Anne Grünewald and Patrick May
Funding agency: Luxembourg National Research Fund (NCER-PD Exploratory Grant)
Funding period: 2017-2019
Amount: € 55,000

“Exploring mitochondrial epigenetics as a cause of mitochondrial dysfunction in Parkinson’s disease”

Co-Principal Investigator: Anne Grünewald
Funding agency: Personalized Medicine Consortium Luxembourg
Funding period: 2018-2019
Amount: € 50,000

“MiRisk-PD – Mitochondrial Risk factor in Parkinson’s disease”; FNR11676395

Co-Principal Investigator: Anne Grünewald
Funding agency: Luxembourg National Research Fund
Funding period: 2018-2020
Amount: € 267,000 (funding for function WP)

“National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD)”

Co-Principal Investigator: Anne Grünewald
Funding agency: Luxembourg National Research Fund
Funding period: 2019-2023
Amount: € ~200,000 (funding within Biomarkers & Mechanisms WP)

“Variable expressivity in SGCE-associated myoclonus dystonia: Insights from epigenetics and transcriptomics”

Co-Principal Investigators: Karen Grütz, Anne Grünewald and Christine Klein

Funding agency: Dystonia Medical Research Foundation
Funding period: 2019-2020
Amount: US$ 74,540

“CAMeSyn – Contribution of astrocyte Metabolism to Synucleopathy in Parkinson’s disease”; C19/BM/13688526

Principal Investigator: Anne Grünewald
Funding agency: Luxembourg National Research Fund
Amount: € 876,000
Funding period: 2020-2023

Boards

Steering Committee member of the Univ. of Luxembourg Leadership Academy (since 2017)

Scientific Advisory Board member for the H2020 SysMedPD consortium (since 2018)

Member of the University Council at the University of Luxembourg (since 2018)

Member of the Gender Equality Committee at the University of Luxembourg (since 2019)

Research Networks

Member of the Genetic Epidemiology of Parkinson’s disease (GeoPD) Consortium

  • Ongoing PhD projects: n=4
  • Completed PhD theses: n=2 (supervision of experimental work)
  • Completed MD theses: n=2 (supervision of experimental work)
  • Completed internships during MSc studies: n=5
  • Completed BSc theses: n=1
  • Completed internships during BSc studies: n=3

Teaching

  • Teaching and supervision in a genetics course for high-school students (9th grade) of the “Katharineum”, Lübeck, Germany (2008)
  • Teaching and supervision in the “Neurogenetics Bioseminar” for Molecular Life Science postgraduate students at the University of Lübeck, Germany (2012)
  • Participation in the lecture series “Neurobiomedicine” for Molecular Life Science postgraduate students at the University of Lübeck, Germany (2012)
  • Attendance of seminar “Introduction to Learning and Teaching in Higher Education” at Newcastle University, UK (2014)
  • Lecturing of the “Molecular Biology 1” and “Molecular Biology 3” courses in the Life Sciences Bachelor, University of Luxembourg (since 2017)
  • PhD seminar on “Mechanisms of cancer and neurodegenerative diseases”, University of Luxembourg (since 2019)

 

Invited talks/selected presentations at international meetings

  • 11th International Congress of the Movement Disorders Society, Istanbul, Turkey, July 2007
  • Annual Genetic Epidemiology of Parkinson’s Disease Consortium Meeting, Tübingen, Germany, July 2009
  • Research seminar, University College London, Institute of Neurology, London, UK, January 2009
  • Annual Genetic Epidemiology of Parkinson’s Disease Consortium Meeting, Toronto, Canada, April 2010
  • Research Seminar, Columbia University, Department of Neurology, New York, USA, June 2010
  • AussieMit 2010, Sydney, Australia, December 2010
  • Research Seminar, Mitochondrial Research Group, University Newcastle, Newcastle, UK, February 2012
  • 16th International Congress of the Movement Disorders Society (GPT1) Dublin, Ireland, June 2012
  • 85th Annual Meeting of the German Society of Neurology, Hamburg, Germany, September 2012
  • Annual Meeting of the Dystonia Medical Research Foundation, New York, USA, April 2013
  • 17th International Congress of the Movement Disorders Society (GPT1), Sydney, Australia, June 2013
  • Annual Genetic Epidemiology of Parkinson’s Disease Meeting, Lübeck, Germany, September 2013
  • 87th Annual Meeting of the German Society of Neurology, Munich, Germany, September 2014
  • Research seminar, LCSB, University of Luxembourg, Luxembourg, October 2014
  • EMBO Workshop on “Mitochondrial DNA and Neurodegeneration”, Sitges, Spain, September 2015
  • Research seminar, Forschungszentrum Jülich, Institute for Computational Medicine, Jülich, November 2016
  • Annual Genetic Epidemiology of Parkinson’s Disease Meeting, Cairns, Australia, September 2017
  • STS Forum, Future Leaders Program 2018, Kyoto, Japan, October 2018
  • 12th Parkinson’s Disease Symposium Cologne, Germany, November 2018
  • Annual Genetic Epidemiology of Parkinson’s Disease Consortium Meeting, Stellenbosch, South Africa, November 2019
  • 5th International Systems Biomedicine Symposium, Esch-sur-Alzette, Luxembourg, November 2019
  1. Berenguer-Escuder C, Grossmann D, Massart F, Antony P, Burbulla LF, Glaab E, Imhoff S, Trinh J, Seibler P, Grünewald A, Krüger R. Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson’s Disease Patients. J Clin Med 2020;12
  2. Ouzren N, Delcambre S, Ghelfi J, Seibler P, Farrer MJ, König IR, Aasly JO, Trinh J, Klein C, Grünewald A. Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers. Ann Neurol 2019;2:324-326.
  3. Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, Serafin A, Rudolph F, Trilck M, Grünewald A, Stanslowsky N, Wegner F, Giorgio V, Lavdas AA, Bodmer R, Pramstaller PP, Klein C, Hicks AA, Pichler I, Philip S. Corrigendum: SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet 2018;7:1225.
  4. Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grünewald A, Almuammar S, König IR, Lill CM, Lohmann K, Klein C, Marras C. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018;12:1857-1870.
  5. Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grünewald A, Almuammar S, König IR, Lill CM, Lohmann K, Klein C, Marras C. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018;12:1857-1870.
  6. Wagner J, Vulinović F, Grünewald A, Unger MM, Möller JC, Klein C, Michel PP, Ries V, Oertel WH, Alvarez-Fischer D. Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons. Neuroscience 2017:137-145.
  7. Zanon A, Kalvakuri S, Rakovic A, Foco L, Guida M, Schwienbacher C, Serafin A, Rudolph F, Trilck M, Grünewald A, Stanslowsky N, Wegner F, Giorgio V, Lavdas AA, Bodmer R, Pramstaller PP, Klein C, Hicks AA, Pichler I, Seibler P. SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet 2017;13:2412-2425.
  8. Grütz K, Seibler P, Weissbach A, Lohmann K, Carlisle FA, Blake DJ, Westenberger A, Klein C, Grünewald A. Faithful SGCE imprinting in iPSC-derived cortical neurons: an endogenous cellular model of myoclonus-dystonia. Sci Rep 2017:41156.
  9. Grünewald A, Klein C. Urinary LRRK2 phosphorylation: Penetrating the thicket of Parkinson disease? Neurology 2016;11:984-985.
  10. Erogullari A, Hollstein R, Seibler P, Braunholz D, Koschmidder E, Depping R, Eckhold J, Lohnau T, Gillessen-Kaesbach G, Grünewald A, Rakovic A, Lohmann K, Kaiser FJ. THAP1, the gene mutated in DYT6 dystonia, autoregulates its own expression. Biochim Biophys Acta 2014;11:1196-1204.
  11. Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, Aerts L, Overbergh L, Grünewald A, Seibler P, Klein C, Gevaert K, Verstreken P, De Strooper B. PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science 2014;6180:203-207.
  12. Lohmann K, Schmidt A, Schillert A, Winkler S, Albanese A, Baas F, Bentivoglio AR, Borngräber F, Brüggemann N, Defazio G, Del Sorbo F, Deuschl G, Edwards MJ, Gasser T, Gómez-Garre P, Graf J, Groen JL, Grünewald A, Hagenah J, Hemmelmann C, Jabusch HC, Kaji R, Kasten M, Kawakami H, Kostic VS, Liguori M, Mir P, Münchau A, Ricchiuti F, Schreiber S, Siegesmund K, Svetel M, Tijssen MA, Valente EM, Westenberger A, Zeuner KE, Zittel S, Altenmüller E, Ziegler A, Klein C. Genome-wide association study in musician’s dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013;7:921-927.
  13. Kasten M, Grünewald A, Klein C. Next-generation phenotyping and genomic incidental findings–reply. JAMA Neurol 2013;12:1590-1591.
  14. Grünewald A, Arns B, Meier B, Brockmann K, Tadic V, Klein C. Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson’s disease? Antioxid Redox Signal 2013;13:1955-1960.
  15. Grünewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol 2013;9:1186-1191.
  16. Freimann K, Zschiedrich K, Brüggemann N, Grünewald A, Pawlack H, Hagenah J, Lohmann K, Klein C, Westenberger A. Mortalin mutations are not a frequent cause of early-onset Parkinson disease. Neurobiol Aging 2013;11:2694.e19-20.
  17. Kumar KR, Blair NF, Vandebona H, Liang C, Ng K, Sharpe DM, Grünewald A, Gölnitz U, Saviouk V, Rolfs A, Klein C, Sue CM. Targeted next generation sequencing in SPAST-negative hereditary spastic paraplegia. J Neurol 2013;10:2516-2522.
  18. Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C, Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A. Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PLoS One 2013;4:e61700.
  19. Weissbach A, Kasten M, Grünewald A, Brüggemann N, Trillenberg P, Klein C, Hagenah J. Prominent psychiatric comorbidity in the dominantly inherited movement disorder myoclonus-dystonia. Parkinsonism Relat Disord 2013;4:422-425.
  20. Lohmann K, Schmidt A, Schillert A, Winkler S, Albanese A, Baas F, Bentivoglio AR, Borngräber F, Brüggemann N, Defazio G, Del Sorbo F, Deuschl G, Edwards MJ, Gasser T, Gómez-Garre P, Graf J, Groen JL, Grünewald A, Hagenah J, Hemmelmann C, Jabusch HC, Kaji R, Kasten M, Kawakami H, Kostic VS, Liguori M, Mir P, Münchau A, Ricchiuti F, Schreiber S, Siegesmund K, Svetel M, Tijssen MA, Valente EM, Westenberger A, Zeuner KE, Zittel S, Altenmüller E, Ziegler A, Klein C. Genome-wide association study in musician’s dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013;7:921-927.
  21. Rakovic A, Shurkewitsch K, Seibler P, Grünewald A, Zanon A, Hagenah J, Krainc D, Klein C. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J Biol Chem 2012;4:2223-2237.
  22. Kumar KR, Ramirez A, Göbel A, Kresojević N, Svetel M, Lohmann K, M Sue C, Rolfs A, Mazzulli JR, Alcalay RN, Krainc D, Klein C, Kostic V, Grünewald A. Glucocerebrosidase mutations in a Serbian Parkinson’s disease population. Eur J Neurol 2012;2:402-405.
  23. Schmidt A, Kumar KR, Redyk K, Grünewald A, Leben M, Münchau A, Sue CM, Hagenah J, Hartmann H, Lohmann K, Christen HJ, Klein C. Two faces of the same coin: benign familial infantile seizures and paroxysmal kinesigenic dyskinesia caused by PRRT2 mutations. Arch Neurol 2012;5:668-670.
  24. Wortmann SB, Vaz FM, Gardeitchik T, Vissers LE, Renkema GH, Schuurs-Hoeijmakers JH, Kulik W, Lammens M, Christin C, Kluijtmans LA, Rodenburg RJ, Nijtmans LG, Grünewald A, Klein C, Gerhold JM, Kozicz T, van Hasselt PM, Harakalova M, Kloosterman W, Barić I, Pronicka E, Ucar SK, Naess K, Singhal KK, Krumina Z, Gilissen C, van Bokhoven H, Veltman JA, Smeitink JA, Lefeber DJ, Spelbrink JN, Wevers RA, Morava E, de Brouwer AP. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012;7:797-802.
  25. Grünewald A, Arns B, Seibler P, Rakovic A, Münchau A, Ramirez A, Sue CM, Klein C. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging 2012;8:1843.e1-7.
  26. Arif B, Grünewald A, Fatima A, Ramirez A, Ali A, Brüggemann N, Würfel J, Rolfs A, Lohmann K, Malik A, Klein C, Naz S. An unusual neurological syndrome of crawling gait, dystonia, pyramidal signs, and limited speech. Mov Disord 2011;12:2279-2283.
  27. Rakovic A, Grünewald A, Voges L, Hofmann S, Orolicki S, Lohmann K, Klein C. PINK1-Interacting Proteins: Proteomic Analysis of Overexpressed PINK1. Parkinsons Dis 2011:153979.
  28. Rakovic A, Grünewald A, Kottwitz J, Brüggemann N, Pramstaller PP, Lohmann K, Klein C. Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 2011;3:e16746.
  29. Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AH, Pramstaller PP, Sue CM, Klein C. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One 2010;9:e12962.
  30. Rakovic A, Grünewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet 2010;16:3124-3137.
  31. Grünewald A, Djarmati A, Lohmann-Hedrich K, Farrell K, Zeller JA, Allert N, Papengut F, Petersen B, Fung V, Sue CM, O’Sullivan D, Mahant N, Kupsch A, Chuang RS, Wiegers K, Pawlack H, Hagenah J, Ozelius LJ, Stephani U, Schuit R, Lang AE, Volkmann J, Münchau A, Klein C. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008;2:331-332.
  32. Paus S, Grünewald A, Klein C, Knapp M, Zimprich A, Janetzky B, Möller JC, Klockgether T, Wüllner U. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson’s disease. Mov Disord 2008;4:599-602.
  33. Orth M, Djarmati A, Bäumer T, Winkler S, Grünewald A, Lohmann‐Hedrich K, Kabakci K, Hagenah J, Klein C, Münchau A. Autosomal dominant myoclonus-dystonia and Tourette syndrome in a family without linkage to the SGCE gene. Movement Disorders 2007;22 (14):2090-2096.
  34. Djarmati A, Guzvić M, Grünewald A, Lang AE, Pramstaller PP, Simon DK, Kaindl AM, Vieregge P, Nygren AO, Beetz C, Hedrich K, Klein C. Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. Mov Disord 2007;12:1708-1714.
  35. Grünewald A, Breedveld GJ, Lohmann-Hedrich K, Rohé CF, König IR, Hagenah J, Vanacore N, Meco G, Antonini A, Goldwurm S, Lesage S, Dürr A, Binkofski F, Siebner H, Münchau A, Brice A, Oostra BA, Klein C, Bonifati V. Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. Neurogenetics 2007;2:103-109.
  36. Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K, Grünewald A, Hilker R, Steinlechner S, Boston H, Kock N, Schneider-Gold C, Kress W, Siebner H, Binkofski F, Lencer R, Münchau A, Klein C. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;6:833-838.
  37. Klein C, Grünewald A, Hedrich K. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2006;7:1129-30; author reply 1129-30.